Literature DB >> 30069622

Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.

Hannah K Knudsen1, Jamie L Studts2.   

Abstract

Increasing numbers of individuals with opioid use disorder (OUD) are insured by Medicaid. Little is known about whether providers of buprenorphine, an evidence-based OUD pharmacotherapy, accept this type of payment. Data are scant regarding whether Medicaid acceptance varies by physician and state-level characteristics. To address these gaps, national survey data from 1174 buprenorphine-prescribing physicians (BPPs) and state characteristics were examined in a multi-level model of Medicaid acceptance. Only 52.0% of BPPs accepted Medicaid for buprenorphine-related office visits. Specialists in addiction and psychiatry were significantly less likely to accept Medicaid than other specialties, as were BPPs delivering buprenorphine in individual medical practice. Perceived adequacy of Medicaid reimbursement was positively associated with accepting Medicaid. Medicaid acceptance was not associated with states' implementation of the Medicaid expansion. Individuals who are covered by Medicaid may face barriers to accessing buprenorphine treatment, which has high public health significance given the ongoing opioid epidemic.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30069622      PMCID: PMC6324979          DOI: 10.1007/s11414-018-9629-4

Source DB:  PubMed          Journal:  J Behav Health Serv Res        ISSN: 1094-3412            Impact factor:   1.505


  54 in total

1.  Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.

Authors:  Cynthia L Arfken; Chris-Ellyn Johanson; Salvatore di Menza; Charles Roberts Schuster
Journal:  J Subst Abuse Treat       Date:  2010-07-03

2.  Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.

Authors:  Paul M Roman; Amanda J Abraham; Hannah K Knudsen
Journal:  Addict Behav       Date:  2011-01-27       Impact factor: 3.913

3.  Medicaid coverage of medications to treat alcohol and opioid dependence.

Authors:  Tami L Mark; Robert Lubran; Elinore F McCance-Katz; Mady Chalk; John Richardson
Journal:  J Subst Abuse Treat       Date:  2015-04-16

4.  Factors determining how early adopter physicians use buprenorphine in treatment.

Authors:  Sharon Reif; Cindy Parks Thomas; Stanley S Wallack
Journal:  J Addict Med       Date:  2007-12       Impact factor: 3.702

5.  Factors associated with Medicaid patients' access to buprenorphine treatment.

Authors:  Jeffrey D Baxter; Robin E Clark; Mihail Samnaliev; Gary Y Leung; Lobat Hashemi
Journal:  J Subst Abuse Treat       Date:  2011-04-02

6.  Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11.

Authors:  Andrew W Dick; Rosalie L Pacula; Adam J Gordon; Mark Sorbero; Rachel M Burns; Douglas Leslie; Bradley D Stein
Journal:  Health Aff (Millwood)       Date:  2015-06       Impact factor: 6.301

7.  Adoption and implementation of new technologies in substance abuse treatment.

Authors:  Paul M Roman; J Aaron Johnson
Journal:  J Subst Abuse Treat       Date:  2002-06

8.  Prescription opioid use disorder and heroin use among 12-34 year-olds in the United States from 2002 to 2014.

Authors:  Silvia S Martins; Luis E Segura; Julian Santaella-Tenorio; Alexander Perlmutter; Miriam C Fenton; Magdalena Cerdá; Katherine M Keyes; Lilian A Ghandour; Carla L Storr; Deborah S Hasin
Journal:  Addict Behav       Date:  2016-08-30       Impact factor: 3.913

9.  Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.

Authors:  Colleen T LaBelle; Steve Choongheon Han; Alexis Bergeron; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2015-06-26

10.  In 2011 nearly one-third of physicians said they would not accept new Medicaid patients, but rising fees may help.

Authors:  Sandra L Decker
Journal:  Health Aff (Millwood)       Date:  2012-08       Impact factor: 6.301

View more
  5 in total

1.  The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.

Authors:  Alex K Gertner; Allison G Robertson; Hendree Jones; Byron J Powell; Pam Silberman; Marisa E Domino
Journal:  Health Serv Res       Date:  2020-03-12       Impact factor: 3.402

2.  The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.

Authors:  Hannah K Knudsen; Jeanie Hartman; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2022-01-29       Impact factor: 4.492

3.  Using conjoint analysis to study health policy changes: An example from a cohort of persons who use drugs.

Authors:  Hannah K Knudsen; Jennifer R Havens
Journal:  Int J Drug Policy       Date:  2021-08-26

4.  A bifurcated opioid treatment system and widening insidious disparities.

Authors:  Erick G Guerrero; Hortensia Amaro; Tenie Khachikian; Mona Zahir; Jeanne C Marsh
Journal:  Addict Behav       Date:  2022-03-02       Impact factor: 4.591

5.  The Emergency Department Longitudinal Integrated Care (ED-LINC) intervention targeting opioid use disorder: A pilot randomized clinical trial.

Authors:  Lauren K Whiteside; Ly Huynh; Sophie Morse; Jane Hall; William Meurer; Caleb J Banta-Green; Hannah Scheuer; Rebecca Cunningham; Mark McGovern; Douglas F Zatzick
Journal:  J Subst Abuse Treat       Date:  2021-11-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.